Alamar Biosciences To Participate In Morgan Stanley 24Th Annual Global Healthcare Conference
Alamar Biosciences' management is scheduled to participate in a fireside chat on Tuesday, September 15, at 4:05 p.m. Eastern Time. Interested parties may access a live and archived webcast of the session on the“Investors” section of the company website at investors.alamarbio.com.
About Alamar Biosciences, Inc.
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISATM technology and the ARGOTM HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as“Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.
Investor contact:
...
Media contact:
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment